What Is an Intravitreal Injection?

How Do "Anti-VEGF" Drugs Stabilize Retinal Vision?

The most common medications used in injections are "anti-VEGF" drugs, such as Avastin, Lucentis, and Eylea. VEGF (Vascular Endothelial Growth Factor) is a protein that causes the body to grow weak, leaky blood vessels under the retina. The injection acts like a "fire extinguisher," neutralizing this protein and allowing the existing fluid to be absorbed back into the body. By drying out the retina, the medication can often restore lost vision or, at the very least, prevent the "scarring" that leads to permanent blindness.

What are the Primary Success Data Trends for Vision Preservation?

Clinical data from the last decade has proven that intravitreal injections are one of the most successful interventions in all of medicine. Studies indicate that before these injections existed, 90 percent of "Wet AMD" patients went legally blind within two years; today, over 90 percent of treated patients maintain their vision. Furthermore, approximately 30 percent of patients experience a significant improvement in their visual acuity after their first three loading doses. These data trends have made the regular injection schedule the mandatory standard of care for preventing retinal blindness.

Why is an Initial "Numbing and Sterilizing" Protocol Mandatory?

The safety of an intravitreal injection depends entirely on the preparation of the eye. The doctor uses powerful numbing drops or a small anesthetic gel to ensure the patient feels nothing more than a localized "pressure" sensation. Most importantly, the eye is cleaned with "Povidone-Iodine" to kill 99.9 percent of the bacteria on the surface. This rigorous sterilizing protocol is the primary reason why the risk of a serious eye infection (endophthalmitis) is incredibly low, occurring in less than 1 in 3,000 injections.

What are the Common Side Effects and Recovery Expectations?

Most patients recover from an injection within twenty-four hours. Common side effects include a "blood spot" on the white of the eye (subconjunctival hemorrhage), which is harmless and looks like a bruise. Patients also report seeing "moving bubbles" or floaters for a few hours as the medication disperses in the vitreous gel. While the eye may feel "scratchy" or gritty for the first day, intense pain is not normal and should always be reported to the clinic immediately.

How Do Clinicians Monitor the Injection Schedule with OCT Scans?

The frequency of injections is managed using high-resolution imaging called OCT (Optical Coherence Tomography). This scan provides a cross-sectional view of the retina, allowing the doctor to see even microscopic amounts of fluid. If the scan shows the retina is "dry," the doctor may extend the time between injections (a "Treat and Extend" protocol). If fluid returns, the schedule is shortened. This data-driven approach ensures that the patient receives only as much medication as they need to keep their vision stable while minimizing the burden of office visits.